EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness

Maria Mannino, Alfredo Piccerillo, Gabriella Fabbrocini, Pietro Quaglino, Giuseppe Argenziano, Emi Dika, Paolo Antonio Ascierto, Giovanni Pellacani, Caterina Longo, Maria Concetta Fargnoli, Luca Bianchi, Piergiacomo Calzavara-Pinton und 7 weitere

Dermatology · 2023

DOI: 10.1159/000531280 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Dermatology, 2023. Verfasst von Maria Mannino und 18 weiteren Autor:innen. Beteiligte Einrichtung: UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche Addominali ed Endrocrino Metaboliche, Fondazione Policlinico Universitario A. Geme…. Hauptthemen laut MEDLINE: Skin Neoplasms, Basal Cell Carcinoma, Antineoplastic Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Advanced basal cell carcinoma (aBCC) represents a complex and clinically heterogeneous group of lesions for which curative surgery and/or radiotherapy is unlikely. Systemic therapy with hedgehog pathway inhibitors (HHIs) changed the treatment landscape for this complex patient population.

Objectives

The aims of the present study are to describe the clinical characteristics of a real-life Italian cohort diagnosed with aBCC and to investigate effectiveness and safety of HHI.

Methods

A multicenter observational study was performed by twelve Italian centers in the period January 1, 2016 – October 15, 2022. Patients aged ≥18 years and diagnosed with aBCC (locally advanced [laBCC] and metastatic BCC [mBCC]) were eligible for the study. Methods for investigating tumor response to HHI included clinical and dermatoscopic evaluation, radiological imaging, and histopathology. For HHI safety assessment, therapy-related adverse events (AEs) were reported and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Results

We enrolled 178 patients under treatment with HHI: 126 (70.8%) and 52 patients (29.2%) received sonidegib and vismodegib, respectively. Comprehensive data on HHI effectiveness and disease outcome were available for 132 (74.1%) of 178 patients: 129 patients had a diagnosis of laBCC (n = 84, sonidegib; n = 45, vismodegib) and 3 patients of mBCC (n = 2, vismodegib; n = 1, sonidegib, off-label). Objective response rate was 76.7% (95% confidence interval [CI]: 82.3–68.7) and 33.3% (95% CI: 88.2–1.7) for laBCC (complete response [CR]: 43/129; PR: 56/129) and mBCC (CR: 0/3; PR: 1/3), respectively. High-risk aBCC histopathological subtypes and occurrence of >2 therapy-related AEs were significantly associated with nonresponse to HHI therapy ([OR: 2.61; 95% CI: 1.09–6.05; p: 0.03] and [OR: 2.74; 95% CI: 1.03–7.9; p: 0.04]), respectively. Majority of our cohort (54.5%) developed at least 1 therapy-related AE, most of which were mild-moderate in severity.

Conclusions

Our results demonstrate the effectiveness and safety profile of HHI and confirm the reproducibility of pivotal trial results in real-life clinical setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsBasal Cell CarcinomaAntineoplastic AgentsHumansAdolescentAdultHedgehog ProteinsReproducibility of ResultsAnilidesBiphenyl CompoundsPyridines

Stichwörter der Autor:innen

Advanced BCCNonmelanoma skin cancerReal-life dataSonidegibVismodegib

Substanzen

Hedgehog ProteinsAnilidesAntineoplastic AgentssonidegibBiphenyl CompoundsPyridinesHhAntag691

Autor:innen und Institutionen

  • UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche Addominali ed Endrocrino Metaboliche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy, mariamannino04@yahoo.it.
  • Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy, mariamannino04@yahoo.it.
  • Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
  • Dermatology Unit, University of Campania "Luigi Vanvitelli", Naples, Italy.

Zitieren

APA

Mannino, M., Piccerillo, A., Fabbrocini, G., Quaglino, P., Argenziano, G., Dika, E., Ascierto, P. A., Pellacani, G., Longo, C., Fargnoli, M. C., Bianchi, L., Calzavara-Pinton, P., Zalaudek, I., Fava, P., Scalvenzi, M., Bocchino, E., Di Stefani, A., Peris, K., & and Collaborators (2023). Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness. Dermatology. https://doi.org/10.1159/000531280

Vancouver

Mannino M, Piccerillo A, Fabbrocini G, Quaglino P, Argenziano G, Dika E, et al. Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness. Dermatology. 2023. doi:10.1159/000531280

BibTeX
@article{Mannino2023,
  author = {Mannino, Maria and Piccerillo, Alfredo and Fabbrocini, Gabriella and Quaglino, Pietro and Argenziano, Giuseppe and Dika, Emi and Ascierto, Paolo Antonio and Pellacani, Giovanni and Longo, Caterina and Fargnoli, Maria Concetta and Bianchi, Luca and Calzavara-Pinton, Piergiacomo and Zalaudek, Iris and Fava, Paolo and Scalvenzi, Massimiliano and Bocchino, Enrico and Di Stefani, Alessandro and Peris, Ketty and and Collaborators, and Collaborators},
  title = {Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness},
  journal = {Dermatology},
  year = {2023},
  doi = {10.1159/000531280}
}
Kostenlos starten →